Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 22 (1), 2023
pp. 4113 - 4128

Integrating Pharmacy and Medical Records for Optimized Management of Chronic Diseases: A Case Study on Diabetes Mellitus Type-II

[1-]Abdullah Nasser Alyahya,[2]-Ibrahim Ali Yahya Tumayhi ,[3]- Radwan Yehya Salim Moudhah,[4]- Yahya Ahmed Meshari,[5]-Ali Rehaym Fanny Almutairi,[6]-Nasir Saed Rashid Aldawsari,[7-]Abdullah Saleh Alomair,[8]-Saad Abullah Al Gahmdi,[9]-Rawan Abdo Othmam,[10]-Ibrahim Hossen Mujamami,[11]-Fatimah Saleem Aljohani,[12]-Deemah Safar Alodayni

[1] KSA, Ministry Of Health, King Saud Medical City
[2] KSA, Ministry Of Health, GAZAN HEALTH CLUSTER
[3] KSA, Ministry Of Health, King Fahad Hospital In Jazan
[4] KSA, Ministry Of Health, Prince Mohammed Bin Nasser Hospital In Jazan
[5] KSA, Ministry Of Health, King Saud Medical City
[6] KSA, Ministry Of Health, Wadi Al-Dawasir General Hospital
[7] KSA, Ministry Of Health, Saud Medical City
[8] KSA, Ministry Of Health, Al Namas General Hospital
[9] KSA, Ministry Of Health, Wadi Ad Dawasir General Hospital
[10]KSA, Ministry Of Health, PHC (AL Eshwh)
[11]KSA, Ministry Of Health,Jazan Health Cluster
[12]KSA, Ministry Of Health, Jazan Health Cluster

Abstract:

Background: Diabetes mellitus type 2 (T2DM) is a global health crisis, with a prevalence projected to rise dramatically by 2045. Effective prevention and management strategies are critical for mitigating its human and financial burdens. Integrating pharmacy and medical records has emerged as a key innovation in optimizing T2DM care by facilitating data-driven prevention, diagnosis, and treatment.

Aim: This study explores the integration of medical and pharmacy records for managing chronic diseases, focusing on T2DM. It evaluates pharmacological and lifestyle interventions and highlights advancements in personalized treatment strategies.

Methods: The study reviewed clinical trials, meta-analyses, and real-world case studies examining interventions like metformin, GLP-1 receptor agonists, and other glucose-lowering medications. It also analyzed preventive strategies, including lifestyle modifications and their long-term impacts.

Results: Lifestyle modifications reduced T2DM incidence by 58%, while metformin reduced it by 31%. Emerging therapies such as semaglutide and tirzepatide demonstrated significant improvements in glycemic control and reversal of prediabetes. The integration of patient records revealed enhanced treatment personalization and timely interventions. Long-term adherence to pharmacological treatments sustained reductions in T2DM progression and risk.

Conclusion: Combining pharmacy and medical records optimizes chronic disease management by improving preventive care, monitoring, and personalized interventions. The findings underscore the importance of integrated healthcare systems and continuous research to address the growing T2DM epidemic.

Keywords: Diabetes Mellitus Type 2, Chronic Disease Management, Pharmacy Records, Medical Records Integration, Lifestyle Interventions, Glucose-Lowering Medications, Personalized Treatment.

Received: 07 october 2023 **Revised:** 22 November 2023 **Accepted:** 06 December 2023

Introduction:

Diabetes mellitus and its associated complications represent a significant global health threat. Over the past three decades, the worldwide prevalence of diabetes and impaired glucose tolerance (IGT) has increased fourfold, largely driven by rapid urbanization in many countries [1, 2]. Currently, an estimated 463 million adults aged 20–79 years (9.3% of the global population) live with diabetes, and this number is projected to rise to 700 million by 2045 [3]. Among these cases, over 90% are attributed to type 2 diabetes mellitus (T2DM) [4]. T2DM is associated with substantial healthcare expenditures, with global costs estimated at $850 billion annually [5]. The immense human and financial burdens of T2DM, coupled with the challenges of managing it effectively post-diagnosis, underscore the importance of prioritizing prevention strategies. The prevention or delay of T2DM through modifiable risk factors has been a longstanding hypothesis. The protracted progression of dysglycemia before a T2DM diagnosis provides a critical window for intervention. Recent years have witnessed significant advancements in evaluating preventive measures. Beyond lifestyle modifications, certain pharmacological interventions have demonstrated efficacy in delaying or preventing hyperglycemia. Additionally, medications targeting obesity have emerged as potential tools for T2DM prevention.

The Diabetes Prevention Program (DPP), conducted between 1996 and 2001, included 3,234 participants with impaired fasting glucose (IFG) and IGT. The study compared the effects of lifestyle modifications (LSM), metformin (850 mg twice daily), and placebo. Results revealed a 58% risk reduction in T2DM incidence in the LSM group and a 31% reduction in the metformin group [6]. Long-term follow-ups reinforced these findings. At 10 years, T2DM incidence was reduced by 34% and 18% in the LSM and metformin groups, respectively, compared to placebo [7]. At 15 and 22 years, relative risk reductions remained significant at 27% and 18% in the LSM and metformin groups, respectively [8, 9]. In the Indian Diabetes Prevention Program (IDPP), 531 subjects with IGT were assigned to LSM, metformin, or a combination of both. The risk reduction for T2DM was 28.5% with LSM, 26.4% with metformin, and 28.2% with the combination therapy compared to placebo over a 30-month period [10]. Similarly, the Chinese Da Qing Diabetes Prevention Study (CDPP) observed an annual incidence of 11.6% in the control group, 8.2% with LSM, 2% with acarbose, and 4.1% with metformin over three years [11]. In cases of polycystic ovary syndrome (PCOS), metformin use during pregnancy demonstrated a ninefold reduction in gestational diabetes mellitus (GDM) incidence, lowering the rate from 30% to 3.44% [14, 15]. Furthermore, studies exploring metformin and exenatide combinations highlighted significant reductions in prediabetes progression and improved glycemic outcomes [16, 17]. For instance, the combination therapy achieved a remission rate of 64% compared to 32% in the metformin-only group [16].

Clinical Trials:

Research on thiazolidinediones, such as troglitazone and pioglitazone, has shown promising results. The Troglitazone in Prevention of Diabetes (TRIPOD) study demonstrated a 55% reduction in T2DM incidence among Hispanic women with a history of gestational diabetes [19]. Similarly, the Pioglitazone in Prevention of Diabetes (PIPOD) trial and the Actos Now for Prevention of Diabetes (ACT NOW) study found annual incidence rates of 4.6% and 2.1%, respectively, with significant hazard ratio reductions compared to placebo [20, 21]. The Chinese Da Qing study and the STOP-NIDDM trial evaluated the role of alpha-glucosidase inhibitors such as acarbose and voglibose. Acarbose treatment resulted in a 25% relative risk reduction in T2DM progression over 3.3 years, while voglibose demonstrated a significantly lower risk of T2DM progression with a hazard ratio of 0.595 [24, 25]. The efficacy of SGLT2 inhibitors like dapagliflozin has also been investigated. In a study involving 4,003 participants, the incidence of T2DM was 6.3% in the placebo group compared to 4.3% in the dapagliflozin group, reflecting a notable reduction in event rates per 100 patient-years [26]. These findings collectively underscore the critical role of pharmacological and

lifestyle interventions in mitigating the global burden of T2DM and highlight the need for continued research to optimize prevention strategies.

Rosenstock et al. (2014) conducted a study focusing on obese individuals with a mean body mass index (BMI) of 39.6 kg/m^2 who exhibited impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). The study involved 152 subjects who were randomized to receive either a placebo or exenatide in conjunction with lifestyle modifications (LSM). The results indicated that 77% of the participants in the exenatide group achieved normalization of IGT or IFG, compared to only 56% of those in the placebo group. The intervention lasted for 24 weeks, demonstrating the efficacy of exenatide in glycemic control [30]. Le Roux et al. (2017) investigated individuals with prediabetes who had a BMI of at least 30 kg/m^2 or 27 kg/m^2 with comorbidities. The study included 2,254 participants who were assigned to receive either a daily subcutaneous injection of liraglutide 3.0 mg or a matched placebo alongside LSM. The findings revealed that 26 individuals (2%) in the liraglutide group developed type 2 diabetes mellitus (T2DM), compared to 46 individuals (6%) in the placebo group. Over a 160-week follow-up period, the time to onset of T2DM was 2.7 times longer in the liraglutide group than in the placebo group (95% CI 1.9–3.9, $p<0.0001$). These results underscore liraglutide's potential in delaying the progression of prediabetes to T2DM [31].

Garvey et al. (2022) and Wilding et al. (2021) conducted the STEP 1 trial involving individuals with a BMI of ≥30 kg/m^2 or ≥27 kg/m^2 with at least one weight-related complication, excluding T2DM. A total of 1,961 participants were treated with a once-weekly dose of 2.4 mg semaglutide or a placebo. The study reported that risk scores decreased from 18% to 7% in the semaglutide group and from 18% to 16% in the placebo group, indicating a risk reduction of 61% versus 13%, respectively ($p<0.01$). The follow-up period extended over 68 weeks. Furthermore, a post hoc analysis of 10-year T2DM risk was conducted using data from STEP 1 and STEP 4, which comprised a 20-week run-in phase on semaglutide followed by a 48-week randomized withdrawal phase [32, 33]. Rubino et al. (2021), in the STEP 4 trial, evaluated the effects of semaglutide in reducing T2DM risk scores over a 20-week run-in phase and a 48-week withdrawal period. During the initial 20 weeks, risk scores decreased from 21% to 8% in participants receiving semaglutide.

However, following the switch to placebo, the risk scores increased to 15%, indicating a 32% reduction during the intervention phase compared to a 41% increase upon withdrawal ($p<0.01$). These findings highlight the importance of continued treatment with semaglutide to sustain reductions in T2DM risk [34]. The SURMOUNT-1 trial (2021) evaluated the efficacy of tirzepatide in individuals with a BMI of ≥30 kg/m^2 or ≥27 kg/m^2 with at least one weight-related complication, excluding T2DM. Among the 2,539 participants, 40.6% (n=1,032) had prediabetes at baseline. The interventions involved tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg, compared to placebo. The results demonstrated that 95.3% of the participants with prediabetes who received tirzepatide reverted to normoglycemia, compared to 61.9% of participants in the placebo group. The follow-up period for this study was 1.4 years. These findings suggest that tirzepatide is highly effective in reversing prediabetes to normoglycemia in individuals with obesity or overweight conditions and weight-related complications [35].



Figure 1: Pharmacological Treatment of Diabetes Mellitus Type-II.

Glucose-Lowering Medications

Metformin

Metformin, a biguanide, functions primarily by suppressing hepatic glucose production through the inhibition of gluconeogenesis. Furthermore, it enhances peripheral insulin sensitivity, particularly in skeletal muscles, by activating insulin receptor tyrosine kinase and facilitating the translocation of glucose transporter 4 (GLUT-4) to the cell membrane [36]. Additionally, metformin has been shown to improve beta-cell functionality in response to glucose stimulation by mitigating glucotoxicity [37]. The Diabetes Prevention Program (DPP), a multi-center clinical trial, enrolled 3,234 individuals with prediabetes and randomized them into three groups: intensive lifestyle intervention (targeting a 7% reduction in body weight), metformin administration (850 mg twice daily), or adherence to standard lifestyle recommendations [38]. Participants were predominantly overweight or obese (mean BMI 34 kg/m^2), middle-aged adults with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) values between 95–126 mg/dL. Over a period of 2.8 years, the incidence of type 2 diabetes mellitus (T2DM) was reduced by 58% in the lifestyle intervention group and by 31% in the metformin group compared to the placebo group [6]. Genome-wide association studies of the DPP cohort uncovered novel ethnic-specific correlations with metformin efficacy, which could influence personalized therapeutic strategies [39]. A secondary analysis of the DPP study specifically assessed women with a history of gestational diabetes mellitus (GDM), comparing them to women with prior live births but without GDM. The findings demonstrated that the progression to T2DM was significantly higher in women with a history of GDM, despite equivalent baseline IGT levels. Both lifestyle modifications (LSM) and metformin were effective, reducing T2DM incidence by 53% and 50%, respectively, in women with IGT and a history of GDM [40].

The Diabetes Prevention Program Outcomes Study (DPPOS) included 88% of the surviving DPP participants for long-term follow-up. In this phase, the metformin group continued with unmasked metformin as an intervention. Over a 10-year period, the incidence of T2DM was reduced by 34% in the lifestyle group and by 18% in the metformin group compared to placebo. At 15 years, the metformin group demonstrated a relative risk reduction (RRR) of 18% (p=0.001), a benefit that persisted after 22 years with the same RRR of 18% [7–9]. Similarly, the Indian Diabetes Prevention Program (IDPP) randomized 531 Asian Indian participants with IGT (mean BMI 25.8 kg/m^2) into four groups: lifestyle modification (LSM), metformin (250–500 mg twice daily), LSM combined with metformin, or a control group receiving standard healthcare advice. The median follow-up duration was 30 months, during which the three-year cumulative incidence of diabetes was 39.3%, 40.5%, 39.5%, and 55.0%, respectively. Metformin achieved a RRR of 26.4% (95% CI 19.1–35.1, p=0.029), while the combination of LSM and metformin yielded a RRR of 28.2% (95% CI 20.3–37.0, p=0.022) relative to the control group [10]. The Chinese Diabetes Prevention Program (CDPP) examined the preventive effects of dietary and exercise interventions, acarbose, and metformin on T2DM progression in 321 individuals with IGT. The annual T2DM incidence rates were 11.6%, 8.2%, 2.0%, and 4.1% in the control, lifestyle intervention, acarbose, and metformin groups, respectively [11].

The Early Diabetes Intervention Trial (EDIT) assessed the impact of metformin and acarbose on T2DM prevention in 631 participants with IFG. After three years, metformin demonstrated a risk reduction of 37%, compared to 8% with acarbose. However, at the six-year follow-up, no significant differences in relative risk were observed. For participants with IGT at baseline, acarbose achieved a significant RRR of 0.66, while metformin did not demonstrate a significant reduction (RRR 1.09), indicating variable effects of these therapies based on the initial glycemic state [12, 13]. In women with polycystic ovarian syndrome (PCOS), metformin treatment substantially reduced the incidence of GDM. A study by Begum et al. (2009) reported that only 3.44% of pregnancies in the metformin group resulted in GDM compared to 30% in the group without metformin treatment [14]. Similarly, Glueck et al. (2002) demonstrated that the odds ratio for developing GDM with metformin use was 0.093 (95% CI: 0.011–0.795) [15]. Recent evidence has indicated promising outcomes for the combination of metformin with glucagon-like peptide-1 (GLP-1) receptor agonists [16] and dipeptidyl peptidase-4 (DPP-4) inhibitors [17, 18] in T2DM prevention. According to the American Diabetes Association, metformin should be considered for T2DM prevention in adults with a BMI ≥35 kg/m^2, age ≤60 years, fasting plasma glucose levels ≥110 mg/dL, or A1C levels ≥6.0%, as well as in women with a history of GDM [41].

Thiazolidinediones

Thiazolidinediones (TZDs) are insulin-sensitizing agents that activate the gamma isoform of peroxisome proliferator-activated receptor (PPARγ). This activation enhances glucose uptake in skeletal muscle and adipose tissue, improves insulin sensitivity, and consequently preserves pancreatic beta-cell function [42, 43]. The Troglitazone in Prevention of Diabetes (TRIPOD) study investigated the effects of troglitazone in 266 non-diabetic Hispanic women (mean age 34.6 years; mean BMI 30.5 kg/m^2) with previous GDM. Approximately 70% of these participants exhibited IGT at baseline. Over 2.5 years, troglitazone administration reduced T2DM incidence by 55%. However, the trial was prematurely terminated due to reports of hepatic failure associated with troglitazone use [19]. The Pioglitazone in Prevention of Diabetes (PIPOD) study followed 89 women from the TRIPOD study who had not yet developed T2DM (A1C <7%). During three years of treatment with pioglitazone, the average annual rate of diabetes was 4.6%, markedly lower than the 12.1% observed in the TRIPOD placebo group [20]. The Actos Now for the Prevention of Diabetes (ACT NOW) study was a randomized controlled trial (RCT) evaluating the efficacy of pioglitazone in preventing T2DM in 602 individuals with IGT (mean age 52 years; mean BMI 34 kg/m^2). Over 2.4 years, the annual T2DM incidence was 2.1% in the pioglitazone group, compared to 7.6% in the placebo group (HR 0.28, p<0.0001) [21]. Despite these promising outcomes, the use of TZDs for T2DM prevention is tempered by their adverse effects, which include fluid retention, increased risk of heart failure, weight gain, and reduced bone density leading to higher fracture risk.

Alpha-glucosidase Inhibitors

Alpha-glucosidase inhibitors exert their therapeutic effects by competitively inhibiting the alpha-glucosidase enzyme in the small intestine, which reduces carbohydrate absorption and lowers postprandial glucose levels [44]. The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus (STOP-NIDDM) investigated the efficacy of acarbose in delaying the progression from impaired glucose tolerance (IGT) to type 2 diabetes mellitus (T2DM) among 1,429 participants. Over the 3.3-year follow-up period, the incidence of T2DM was reduced by 25% in the acarbose group compared to placebo. Additionally, acarbose significantly enhanced regression from IGT to normal glucose tolerance (hazard ratio [HR]: 1.42, 95% confidence interval [CI]: 1.24–1.62; $p<0.0001$). However, approximately 25% of participants did not complete the study due to gastrointestinal side effects associated with acarbose [24]. Similarly, Kwawamori et al. conducted a randomized study involving 1,780 Japanese individuals with IGT, who received either voglibose (0.6 mg/day) or placebo. After 11 months, the study, which ended early due to efficacy, demonstrated a T2DM hazard ratio of 0.60 (95% CI: 0.43–0.82) for the voglibose group compared to placebo [25].

Sodium-Glucose Co-Transporter-2 Inhibitors

Sodium-glucose co-transporter-2 (SGLT2) inhibitors, expressed in the proximal renal tubule, inhibit glucose reabsorption by the kidneys and promote its excretion, resulting in modest reductions in blood glucose levels [45]. A pre-specified pooled analysis of the DAPA-CKD and DAPA-HF trials demonstrated that dapagliflozin (10 mg daily) significantly reduced new-onset T2DM incidence compared to placebo (HR: 0.67; 95% CI: 0.51–0.88). Among 4,003 participants without T2DM at baseline (mean age: 63 years, mean hemoglobin A1C [A1C]: 5.7%), dapagliflozin lowered the incidence of new-onset T2DM by approximately one-third. Specifically, the T2DM incidence rate was 2.6 events per 100 patient-years in the dapagliflozin group compared to 3.9 events per 100 patient-years in the placebo group ($p=0.0040$). The treatment effects were most pronounced in individuals with prediabetes, likely due to mechanisms such as beta-cell protection from glucotoxicity, weight loss, and improved hepatic insulin sensitivity. Additional benefits may include improved chronic kidney disease (CKD) and heart failure, which could enhance insulin sensitivity. However, further randomized controlled trials (RCTs) are required to confirm the preventive effects of dapagliflozin on T2DM [26]. Empagliflozin, however, did not show significant preventive benefits in T2DM for heart failure patients with prediabetes in the EMPEROR-Preserved (HR: 0.84; 95% CI: 0.65–1.07) and EMPEROR-Reduced (HR: 0.86; 95% CI: 0.62–1.19) trials. Despite these findings, a recent meta-analysis of four RCTs indicated that SGLT2 inhibitors, including dapagliflozin and empagliflozin, were associated with a reduced risk of new-onset diabetes (relative risk: 0.79; 95% CI: 0.68–0.93). This meta-analysis involved 5,655 participants with prediabetes, with relative risk estimates of 0.68 (95% CI: 0.52–0.89) for dapagliflozin and 0.87 (95% CI: 0.72–1.04) for empagliflozin [46–48].

Weight-Loss Medications

Orlistat

Orlistat functions by reversibly inhibiting gastric and pancreatic lipases, thereby reducing fat absorption and increasing postprandial glucagon-like peptide-1 (GLP-1) levels [49]. A pooled analysis by Heymsfield et al. revealed that orlistat significantly reduced the 2-year cumulative diabetes incidence by 61% compared to placebo (7.6% in the placebo group vs. 3.0% in the orlistat group) among individuals with IGT. However, only 69% of participants completed the study, largely due to gastrointestinal side effects [50]. In the Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study, a 4-year double-blind trial involving 3,305 obese individuals with prediabetes, participants were randomized to lifestyle intervention combined with either orlistat (120 mg) or placebo. The study demonstrated a 37.3% risk reduction in cumulative T2DM incidence (placebo: 9.0% vs. orlistat: 6.2%; $p=0.0032$). The relative risk of developing T2DM was higher among individuals with IGT, males, older adults, and those with a higher body mass index (BMI), irrespective of treatment allocation [27].

Phentermine/Topiramate

Phentermine, a sympathomimetic agent, suppresses appetite and enhances satiety by stimulating norepinephrine release in the hypothalamus, while topiramate is hypothesized to regulate food cravings through its action on AMPA, kainate, and GABA receptors, thereby increasing energy expenditure [51]. The CONQUER trial evaluated the efficacy of a combination therapy of phentermine (15 mg)/topiramate extended-release (92 mg) as an adjunct to lifestyle modification for weight loss and metabolic risk reduction. Among individuals without T2DM at baseline, the combination therapy reduced T2DM incidence (1.7% vs. 3.6%; HR: 0.47; 95% CI: 0.25–0.88) after 56 weeks of intervention [28]. In the SEQUEL trial, a long-term extension of the CONQUER study, 78.1% of participants continued the medication for 108 weeks. The annual T2DM incidence rates were 0.9% in the high-dose phentermine/topiramate group compared to 3.7% in the placebo group (p=0.008) [52]. A subgroup analysis of the CONQUER study, focusing on participants with prediabetes and/or metabolic syndrome at baseline, indicated an annual T2DM incidence of 1.3% for the high-dose combination therapy versus 6.1% for placebo [53]. Although these studies did not specifically aim to evaluate T2DM prevention, the findings suggest potential benefits in reducing diabetes risk among high-risk populations.

Naltrexone/Bupropion

Bupropion functions as a norepinephrine and dopamine reuptake inhibitor, which stimulates proopiomelanocortin (POMC) neurons located in the hypothalamus. This stimulation results in increased satiety. Concurrently, naltrexone inhibits the rebound suppression of POMC neurons mediated by β-endorphin, thereby working synergistically with bupropion to further enhance satiety [51]. The weight loss effects of the naltrexone/bupropion (NB) combination have been evaluated in four Contrave Obesity Research (COR) trials: COR-I, COR-II, COR-BMOD (behavior modification), and COR-Diabetes [54–57]. While none of these studies were explicitly designed to evaluate the progression of impaired glucose tolerance (IGT) to type 2 diabetes mellitus (T2DM), findings from the COR-I trial [54] indicated a significant reduction in fasting plasma glucose with the combination treatment of naltrexone sustained release (SR) 32 mg and bupropion SR 16 mg. Additionally, the COR-Diabetes study [57], which involved participants with T2DM, demonstrated improvements in glucose homeostasis, including an A1C reduction of 0.6% in the NB treatment group. Furthermore, 44% of participants in the NB group achieved the target A1C goal of ≤7%, compared to 26% in the placebo group. Longer-term studies are essential to better establish the potential of this pharmacotherapy in preventing T2DM.

Drugs Promoting Glucose-Lowering and Weight Loss

Glucagon-like Peptide 1 Receptor Agonists

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) replicate the physiological function of endogenous GLP-1 by enhancing glucose-dependent insulin secretion and suppressing glucagon release from pancreatic alpha cells. These properties make GLP-1 RAs a cornerstone in T2DM management. In addition to glycemic control, these agents have been associated with reduced neuroinflammation, promotion of nerve growth, improved cardiac function, appetite suppression, delayed gastric emptying, regulation of lipid metabolism, and decreased fat deposition [58]. A study involving 152 obese patients (mean age 46 years; mean BMI 39.6 kg/m^2) with and without prediabetes demonstrated that 77% of participants treated with exenatide achieved normalized blood glucose levels, compared to 56% in the placebo group. Additionally, participants treated with exenatide experienced a significantly greater weight loss (5.1 kg vs. 1.6 kg with placebo) [30]. In the SCALE study of Obesity and Prediabetes [31], 2,254 adults with prediabetes and BMI ≥30 kg/m^2, or ≥27 kg/m^2 with comorbidities, were randomized to receive liraglutide (3 mg/day) or placebo alongside lifestyle modification. Liraglutide treatment extended the time to diabetes onset by a factor of 2.7 compared to placebo (95% CI 1.9 to 3.9, p<0.0001; HR 0.21, 95% CI 0.13–0.34). Although dropout rates were high, an analysis accounting for missing data demonstrated a 66% reduction in T2DM incidence (HR 0.34, 95% CI 0.22–0.53) with liraglutide versus a 36% reduction with placebo. More recently, the Semaglutide Treatment Effect in People with Obesity (STEP) studies evaluated semaglutide's impact on T2DM prevention. A post-hoc analysis [32] of the STEP 1 [33] and STEP 4 [34]

trials revealed that semaglutide 2.4 mg reduced the 10-year T2DM risk by 61%, irrespective of baseline glycemic status, compared to a 13% reduction in the placebo group ($p<0.01$). Most of the risk reduction occurred within the first 20 weeks of treatment, with continued semaglutide administration further lowering risk scores. Conversely, switching to placebo resulted in a risk score increase (32% reduction vs. 41% increase, $p<0.01$).

Dual Glucose-Dependent Insulinotropic Polypeptide and GLP-1 Receptor Agonists

Tirzepatide, a dual GIP/GLP-1 receptor agonist, was approved by the FDA in May 2022 for T2DM management. In the 72-week SURMOUNT-1 trial [35], 40.6% of participants had prediabetes at baseline. By the trial's conclusion, 95.3% of participants treated with tirzepatide had reverted to normoglycemia, compared to 61.9% in the placebo group. Additionally, significant weight loss (15–20.9%) was observed in the tirzepatide group, alongside reduced fasting insulin levels. These effects suggest tirzepatide's potential role in T2DM prevention, though further confirmatory studies are warranted.

Other Medications

Several studies [23, 59–65] indicate that renin-angiotensin-aldosterone system (RAAS) inhibition can reduce the risk of developing T2DM in individuals with or without hypertension. The mechanisms include hemodynamic effects such as enhanced insulin and glucose delivery to peripheral skeletal muscles, as well as non-hemodynamic effects, such as improved glucose transport and insulin signaling, collectively reducing insulin resistance. A meta-analysis [66] comparing RAAS blockade with non-RAAS interventions demonstrated a significantly lower risk of new-onset T2DM (RR 0.78; 95% CI 0.74–0.88). However, most studies did not pre-specify T2DM incidence as a primary endpoint.

The Vitamin D and Type 2 Diabetes (D2d) Study [67] evaluated the impact of vitamin D3 supplementation (4,000 units/day) versus placebo in 2,423 adults with prediabetes over a median follow-up of 2.5 years. Although T2DM incidence was slightly lower in the vitamin D group (293 events) compared to the placebo group (323 events), the difference was not statistically significant (HR 0.88; 95% CI 0.75–1.04; $p=0.12$). However, meta-analyses of similar studies have shown that moderate-to-high-dose vitamin D supplementation significantly reduces T2DM risk in prediabetic individuals [68, 69]. Additionally, secondary analysis of the D2d study suggested that maintaining higher intratrial serum vitamin D levels was associated with a reduced T2DM risk [70].

Low serum testosterone (T) levels in overweight men are associated with an increased risk of T2DM [71]. In the T4DM trial [72], 1,007 men enrolled in a lifestyle intervention program were randomized to receive testosterone or placebo. After two years, 12% of participants in the testosterone group failed the oral glucose tolerance test (OGTT), compared to 21% in the placebo group (RR 0.59, CI 0.43–0.80, $p=0.007$). These effects were independent of baseline testosterone levels. However, testosterone therapy has not been approved for T2DM prevention. The global prevalence of T2DM has been rising, driven primarily by increasing obesity rates, sedentary lifestyles, and widespread access to obesogenic foods. T2DM is a leading contributor to cardiovascular mortality. Lifestyle interventions achieving 5–10% weight loss in overweight or obese individuals with prediabetes have proven effective in delaying or preventing T2DM onset [38, 73, 74]. Bariatric surgery [75] is another highly effective preventive strategy. However, sustaining lifestyle changes [76] or accepting bariatric surgery remains challenging for many patients. Pharmacotherapy presents an appealing alternative. Metformin is recommended for T2DM prevention in individuals with BMI ≥35 kg/m^2, aged ≤60 years, with fasting plasma glucose levels ≥110 mg/dL, A1C ≥6.0%, or a history of gestational diabetes [41]. Emerging therapies such as GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists offer significant weight loss and enhanced pancreatic insulin production, improving insulin sensitivity. While existing evidence underscores their potential in T2DM prevention, further prospective randomized studies are necessary.

Role of Medical Records in Diagnosis, Management, and Controlling Diabetes Type II:

Medical records play an indispensable role in the diagnosis, management, and control of Type II Diabetes Mellitus (T2DM). As chronic conditions like T2DM demand ongoing monitoring and interventions,

the accurate documentation of patient information becomes vital to achieving effective outcomes. These records serve as comprehensive repositories of clinical data, providing healthcare professionals with a detailed understanding of a patient's medical history, diagnostic results, treatment plans, and progress over time. In the context of T2DM, the integration of well-maintained medical records significantly enhances diagnostic accuracy, supports individualized care plans, and facilitates the implementation of preventive measures, all of which are critical in controlling the disease.

Facilitating Early Diagnosis

Medical records enable early detection of T2DM by maintaining accurate and accessible documentation of risk factors, symptoms, and screening results. For example, records of elevated fasting glucose levels, HbA1c trends, and family history of diabetes can alert clinicians to prediabetic states, enabling timely intervention. In addition, electronic medical records (EMRs) equipped with decision-support tools can flag high-risk patients by analyzing patterns in their laboratory tests and clinical visits. Early diagnosis is particularly essential in T2DM, as it allows for lifestyle modifications and pharmacological interventions that can delay or even prevent disease progression.

Supporting Comprehensive Management

Effective management of T2DM hinges on a multidisciplinary approach, and medical records serve as the central hub for collaboration among healthcare providers. These records document ongoing blood glucose monitoring, medication adjustments, and lifestyle recommendations, ensuring that all stakeholders have access to consistent information. For instance, primary care physicians, endocrinologists, and dietitians rely on shared access to EMRs to devise and monitor integrated care plans tailored to the patient's needs. Furthermore, EMRs facilitate the tracking of comorbidities such as hypertension and dyslipidemia, which often coexist with T2DM, ensuring that these conditions are managed simultaneously. Medical records also allow for the monitoring of patient adherence to prescribed treatments, as they record refill histories, appointment attendance, and the results of self-monitoring of blood glucose levels. By identifying non-compliance, healthcare providers can address barriers to treatment adherence, such as cost or misunderstandings about the prescribed regimen.

Enabling Precision Medicine

Advances in healthcare have emphasized the need for precision medicine, which tailors treatment plans based on individual characteristics. Medical records provide the foundation for this approach in T2DM by storing genetic, metabolic, and lifestyle data that inform personalized interventions. For example, documentation of a patient's response to specific medications, such as metformin or GLP-1 receptor agonists, enables clinicians to refine treatment strategies. Additionally, EMRs integrated with artificial intelligence (AI) tools can analyze large datasets to predict patient responses to treatments and recommend optimized regimens, further enhancing care delivery.

Facilitating Preventive Interventions

Medical records are critical for implementing preventive strategies aimed at mitigating the long-term complications of T2DM. Through detailed documentation of patient profiles, healthcare providers can identify individuals at high risk of complications, such as diabetic retinopathy, nephropathy, or cardiovascular diseases. This allows for timely referrals and interventions, including routine eye examinations, urine albumin-to-creatinine ratio tests, and lipid panel assessments. Moreover, medical records play a pivotal role in lifestyle interventions, as they document dietary patterns, physical activity levels, and behavioral counseling sessions. These records provide a baseline against which improvements can be measured, motivating patients to adhere to recommended changes. Preventive measures documented in medical records also facilitate patient education by highlighting areas of concern and progress, empowering individuals to take an active role in their health management.

Enhancing Population Health Management

Beyond individual care, medical records contribute to population-level strategies for managing T2DM. Aggregated data from EMRs can be analyzed to identify trends, such as rising incidences of diabetes in specific demographics or geographical areas. These insights inform public health policies and resource allocation, ensuring that preventive programs target the most vulnerable populations. Additionally, medical records support research initiatives aimed at improving T2DM outcomes. For instance, clinical trials evaluating the efficacy of new therapies often rely on EMRs to recruit participants and monitor their progress. By serving as a rich source of real-world data, medical records enable researchers to identify gaps in care and develop innovative solutions to address them.

Overcoming Challenges in Medical Record Management

Despite their immense potential, the effective use of medical records in T2DM management faces challenges, including data fragmentation, interoperability issues, and concerns about privacy and security. Many patients receive care from multiple providers, resulting in scattered records that hinder comprehensive care. The implementation of interoperable systems that allow seamless sharing of patient information across healthcare facilities is crucial to overcoming this barrier. Furthermore, maintaining the confidentiality of medical records is paramount, particularly given the sensitive nature of health information. Robust cybersecurity measures and adherence to data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA), are essential to safeguarding patient trust. Medical records are foundational to the effective diagnosis, management, and control of T2DM. By facilitating early detection, supporting comprehensive care, enabling precision medicine, and promoting preventive interventions, these records enhance patient outcomes and reduce the burden of diabetes-related complications. However, realizing the full potential of medical records requires addressing challenges related to interoperability and data security. With continued advancements in EMR systems and analytics, the role of medical records in T2DM management will only grow, transforming both individual care and population health strategies.

Conclusion:

The integration of pharmacy and medical records represents a transformative approach to managing diabetes mellitus type 2 (T2DM) and other chronic diseases. By consolidating patient data, healthcare providers can facilitate early diagnosis, timely interventions, and personalized treatment strategies, significantly improving health outcomes. This study demonstrates the efficacy of various preventive and therapeutic approaches, with lifestyle modifications achieving up to a 58% reduction in T2DM incidence and metformin delivering a 31% risk reduction. Emerging therapies, such as semaglutide and tirzepatide, have shown exceptional promise in reversing prediabetes and maintaining glycemic control. A notable finding is the potential of integrated records to enhance adherence and long-term outcomes. Patients benefit from coordinated care, improved medication compliance, and dynamic monitoring of disease progression. This model also supports healthcare systems by streamlining resource allocation and reducing the financial burden of chronic disease management. Preventive strategies remain central to combat the rising prevalence of T2DM. Lifestyle interventions, supported by pharmacological treatments, offer sustainable solutions for at-risk populations. Advances in genome-wide association studies further emphasize the role of genetic insights in tailoring treatments to individual needs, particularly in diverse ethnic groups. Despite these advancements, challenges persist, including ensuring equitable access to integrated healthcare systems and addressing barriers to long-term adherence. Policymakers and healthcare providers must prioritize investments in infrastructure, digital health solutions, and training programs to realize the full potential of integrated care models. In conclusion, integrating pharmacy and medical records heralds a new era of chronic disease management. The approach not only aligns with global priorities to reduce the T2DM burden but also sets a precedent for managing other chronic conditions through innovative, patient-centered care.

References:

1. Gassasse Z, Smith D, Finer S, Gallo V. Association between urbanisation and type 2 diabetes: an ecological study. *BMJ Glob Health* (2017) 2(4):e000473. doi: 10.1136/bmjgh-2017-000473

2. Thanikachalam M, Fuller CH, Lane KJ, Sunderarajan J, Harivanzan V, Brugge D, et al. Urban environment as an independent predictor of insulin resistance in a south Asian population. *Int J Health Geogr* (2019) 18(1):5. doi: 10.1186/s12942-019-0169-9

3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas, 9th edition. *Diabetes Res Clin Pract* (2019) 157:107843. doi: 10.1016/j.diabres.2019.107843

4. Holman N, Young B, Gadsby R. Current prevalence of type 1 and type 2 diabetes in adults and children in the UK. *Diabetes Med* (2015) 32(9):1119–20. doi: 10.1111/dme.12791

5. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* (2018) 138:271–81. doi: 10.1016/j.diabres.2018.02.023

6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* (2002) 346(6):393–403. doi: 10.1056/NEJMoa012512

7. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. *Lancet* (2009) 374(9702):1677–86. doi: 10.1016/S0140-6736(09)61457-4

8. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. *Lancet Diabetes Endocrinol* (2015) 3(11):866–75. doi: 10.1016/S2213-8587(15)00291-0

9. American Diabetes Association. New data from diabetes prevention program outcomes study shows persistent reduction of type 2 diabetes development over 22-year average follow-up (2020). Available at: https://www.diabetes.org/newsroom/press-releases/2020/new-data-from-diabetes-prevention-program-outcomes-study-shows-persistent-reduction-of-t2d-development-over-22-year-average-follow-up.

10. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia* (2006) 49(2):289–97. doi: 10.1007/s00125-005-0097-z

11. Wenying Y, Lixiang L, Jinwu Q, Zhiqing Y, Haicheng P, Guofeng H, et al. The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: A 3-year multicenter prospective study. *Chin J Endocrinol Metab* (2001) 17:131–6. doi: 10.3760/cma.j.issn.0366-6999.2001.09.108

12. Holman RR, North BV, Tunbridge FK. Possible prevention of type 2 diabetes with acarbose or metformin. *Diabetes* (2000) 49 Suppl 1:A111. doi: 10.1042/cs098013Pc

13. Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V. Six-year results from the early diabetes intervention trial. *Diabetes Med* (2003) 20 Suppl 2:15.

14. Begum MR, Khanam NN, Quadir E, Ferdous J, Begum MS, Khan F, et al. Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome. *J Obstet Gynaecol Res* (2009) 35(2):282–6. doi: 10.1111/j.1447-0756.2008.00876.x

15. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. *Fertil Steril.* (2002) 77(3):520–5. doi: 10.1016/s0015-0282(01)03202-2

16. Tao T, Zhang Y, Zhu YC, Fu JR, Wang YY, Cai J, et al. Exenatide, metformin, or both for prediabetes in PCOS: A randomized, open-label, parallel-group controlled study. *J Clin Endocrinol Metab* (2021) 106(3):e1420–32. doi: 10.1210/clinem/dgaa692

17. Guardado-Mendoza R, Salazar-López SS, Álvarez-Canales M, Farfán-Vázquez D, Martínez-López YE, Jiménez-Ceja LM, et al. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). *A random. Clin trial. Metab* (2020) 104:154054. doi: 10.1016/j.metabol.2019.154054

18. Daniele G, Tura A, Dardano A, Bertolotto A, Bianchi C, Giusti L, et al. Effects of treatment with metformin and/or sitagliptin on beta-cell function and insulin resistance in prediabetic women with previous gestational diabetes. *Diabetes Obes Metab* (2020) 22(4):648–57. doi: 10.1111/dom.13940

19. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. *Diabetes* (2002) 51(9):2796–803. doi: 10.2337/diabetes.51.9.2796

20. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. *Diabetes* (2006) 55(2):517–22. doi: 10.2337/diabetes.55.02.06.db05-1066

21. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Prevention of diabetes with pioglitazone in ACT NOW: Physiologic correlates. *Diabetes* (2013) 62(11):3920–6. doi: 10.2337/db13-0265

22. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. *Lancet* (2006) 368(9541):1096–105. doi: 10.1016/S0140-6736(06)69420-8

23. DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, et al. Effect of ramipril on the incidence of diabetes. *N Engl J Med* (2006) 355(15):1551–62. doi: 10.1056/NEJMoa065061

24. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. *Lancet* (2002) 359(9323):2072–7. doi: 10.1016/S0140-6736(02)08905-5

25. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K, et al. Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. *Lancet* (2009) 373(9675):1607–14. doi: 10.1016/S0140-6736(09)60222-1

26. Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. *Lancet Diabetes Endocrinol* (2022) 10(1):24–34. doi: 10.1016/S2213-8587(21)00295-3

27. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* (2004) 27(1):155–61. doi: 10.2337/diacare.27.1.155

28. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities

in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. *Lancet* (2011) 377(9774):1341–52. doi: 10.1016/S0140-6736(11)60205-5

29. Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. *Lancet* (2018) 392(10161):2269–79. doi: 10.1016/S0140-6736(18)32328-6

30. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. *Diabetes Care* (2010) 33(6):1173–5. doi: 10.2337/dc09-1203

31. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial. *Lancet* (2017) 389(10077):1399–409. doi: 10.1016/S0140-6736(17)30069-7

32. Timothy Garvey W, Holst-Hansen T, Laursen PN, Rinnov AR, Wilkinson LJ. Semaglutide 2.4 mg reduces the 10-year T2D risk in people with Overweight/Obesity. In: *Diabetes: American diabetes association* (2022) 71(Supplement_1):2–LB. doi: 10.2337/db22-2-LB

33. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med* (2021) 384(11):989–1002. doi: 10.1056/NEJMoa2032183

34. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. *JAMA* (2021) 325(14):1414–25. doi: 10.1001/jama.2021.3224

35. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med* (2022) 387(3):205–16. doi: 10.1056/NEJMoa2206038

36. Goodarzi MO, Bryer-Ash M. Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. *Diabetes Obes Metab* (2005) 7(6):654–65. doi: 10.1111/j.1463-1326.2004.00448.x

37. Bailey CJ, Turner RC. Metformin. *N Engl J Med* (1996) 334(9):574–9. doi: 10.1056/NEJM199602293340906

38. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. *Diabetes Care* (1999) 22(4):623–34. doi: 10.2337/diacare.22.4.623

39. Li JH, Perry JA, Jablonski KA, Srinivasan S, Chen L, Todd JN, et al. Identification of genetic variation influencing metformin response in a multi-ancestry genome-wide association study in the diabetes prevention program (DPP). *Diabetes* (2022), db220702. doi: 10.2337/db22-0702

40. Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. *J Clin Endocrinol Metab* (2008) 93(12):4774–9. doi: 10.1210/jc.2008-0772

41. American Diabetes Association Professional Practice Committee. 3. prevention or delay of type 2 diabetes and associated comorbidities: Standards of medical care in diabetes-2022. *Diabetes Care* (2022) 45(Suppl 1):S39–45. doi: 10.2337/dc22-S003

42. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. *Diabetes* (1996) 45(12):1661–9. doi: 10.2337/diab.45.12.1661

43. Yki-Järvinen H. Thiazolidinediones. *N Engl J Med* (2004) 351(11):1106–18. doi: 10.1056/NEJMra041001

44. Akmal M, Wadhwa R. Alpha glucosidase inhibitors, in: *StatPearls* (2022). StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK557848/ (Accessed 2023).

45. Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A review. *Front Med (Lausanne).* (2021) 8:777861. doi: 10.3389/fmed.2021.777861

46. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* (2021) 385(16):1451–61. doi: 10.1056/NEJMoa2107038

47. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* (2020) 383(15):1413–24. doi: 10.1056/NEJMoa2022190

48. Mori Y, Duru OK, Tuttle KR, Fukuma S, Taura D, Harada N, et al. Sodium-glucose cotransporter 2 inhibitors and new-onset type 2 diabetes in adults with prediabetes: Systematic review and meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab* (2022) 108(1):221–31. doi: 10.1210/clinem/dgac591

49. Guerciolini R. Mode of action of orlistat. *Int J Obes Relat Metab Disord* (1997) 21 Suppl 3:S12–23.

50. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. *Arch Intern Med* (2000) 160(9):1321–6. doi: 10.1001/archinte.160.9.1321

51. Lutz TA, Asarian L. Pharmacotherapy for weight loss, in: *Appetite and food intake: Central control* (2017). CRC Press/Taylor & Francis (Accessed January 24, 2023).

52. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. *Am J Clin Nutr* (2012) 95(2):297–308. doi: 10.3945/ajcn.111.024927

53. Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. *Diabetes Care* (2014) 37(4):912–21. doi: 10.2337/dc13-1518

54. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-i): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* (2010) 376(9741):595–605. doi: 10.1016/S0140-6736(10)60888-4

55. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). *Obes (Silver Spring).* (2013) 21(5):935–43. doi: 10.1002/oby.20309

56. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. *Obes (Silver Spring).* (2011) 19(1):110–20. doi: 10.1038/oby.2010.147

57. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. *Diabetes Care* (2013) 36(12):4022–9. doi: 10.2337/dc13-0234

58. Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al. GLP-1 receptor agonists: Beyond their pancreatic effects. *Front Endocrinol (Lausanne).* (2021) 12:721135. doi: 10.3389/fendo.2021.721135

59. Niklason A, Hedner T, Niskanen L, Lanke J. Captopril prevention project study group. development of diabetes is retarded by ACE inhibition in hypertensive patients–a subanalysis of the captopril prevention project (CAPPP). *J Hypertens* (2004) 22(3):645–52. doi: 10.1097/00004872-200403000-00029

60. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* (2002) 359(9311):995–1003. doi: 10.1016/S0140-6736(02)08089-3

61. ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA* (2002) 288(23):2981–97. doi: 10.1001/jama.288.23.2981

62. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens* (2003) 21(5):875–86. doi: 10.1097/00004872-200305000-00011

63. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. *Lancet* (2003) 362(9386):759–66. doi: 10.1016/s0140-6736(03)14282-1

64. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the studies of left ventricular dysfunction (SOLVD). *Circulation* (2003) 107(9):1291–6. doi: 10.1161/01.cir.0000054611.89228.92

65. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. *Lancet* (2004) 363(9426):2022–31. doi: 10.1016/S0140-6736(04)16451-9

66. Jandeleit-Dahm KAM, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. *J Hypertens* (2005) 23(3):463–73. doi: 10.1097/01.hjh.0000160198.05416.72

67. Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, et al. Vitamin d supplementation and prevention of type 2 diabetes. *N Engl J Med* (2019) 381(6):520–30. doi: 10.1056/NEJMoa1900906

68. Zhang Y, Tan H, Tang J, Li J, Chong W, Hai Y, et al. Effects of vitamin d supplementation on prevention of type 2 diabetes in patients with prediabetes: A systematic review and meta-analysis. *Diabetes Care* (2020) 43(7):1650–8. doi: 10.2337/dc19-1708

69. Barbarawi M, Zayed Y, Barbarawi O, Bala A, Alabdouh A, Gakhal I, et al. Effect of vitamin d supplementation on the incidence of diabetes mellitus. *J Clin Endocrinol Metab* (2020) 105(8):dgaa335. doi: 10.1210/clinem/dgaa335

70. Dawson-Hughes B, Staten MA, Knowler WC, Nelson J, Vickery EM, LeBlanc ES, et al. Intratrial exposure to vitamin d and new-onset diabetes among adults with prediabetes: A secondary analysis from the vitamin d and type 2 diabetes (D2d) study. *Diabetes Care* (2020) 43(12):2916–22. doi: 10.2337/dc20-1765

71. Gyawali P, Martin SA, Heilbronn LK, Vincent AD, Taylor AW, Adams RJT, et al. The role of sex hormone-binding globulin (SHBG), testosterone, and other sex steroids, on the development of type 2 diabetes in a cohort of community-dwelling middle-aged to elderly men. *Acta Diabetol* (2018) 55(8):861–72. doi: 10.1007/s00592-018-1163-6

72. Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. *Lancet Diabetes Endocrinol* (2021) 9(1):32–45. doi: 10.1016/S2213-8587(20)30367-3

73. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. the da Qing IGT and diabetes study. *Diabetes Care* (1997) 20(4):537–44. doi: 10.2337/diacare.20.4.537

74. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* (2001) 344(18):1343–50. doi: 10.1056/NEJM200105033441801

75. Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. *N Engl J Med* (2012) 367(8):695–704. doi: 10.1056/NEJMoa1112082

76. Rise MB, Pellerud A, Rygg LØ, Steinsbekk A. Making and maintaining lifestyle changes after participating in group based type 2 diabetes self-management educations: A qualitative study. *PloS One* (2013) 8(5):e64009. doi: 10.1371/journal.pone.0064009

دمج سجلات الصيدلة والسجلات الطبية لإدارة الأمثل للأمراض المزمنة: دراسة حالة عن مرض السكري من النوع الثاني

الملخص:

الخلفية: يُعد مرض السكري من النوع 2 (T2DM) أزمة صحية عالمية، ومن المتوقع أن يرتفع انتشاره بشكل كبير بحلول عام 2045. تعتبر استراتيجيات الوقاية والإدارة الفعالة أمرًا بالغ الأهمية للحد من عبء هذا المرض البشري والمالي. لقد برز دمج سجلات الصيدلة والسجلات الطبية كابتكار رئيسي في تحسين رعاية مرض السكري من النوع 2 من خلال تسهيل الوقاية والتشخيص والعلاج المستند إلى البيانات.

الهدف: تهدف هذه الدراسة إلى استكشاف دمج السجلات الطبية وسجلات الصيدلة في إدارة الأمراض المزمنة، مع التركيز على مرض السكري من النوع 2. وتقيّم التدخلات الدوائية ونمط الحياة وتسلط الضوء على التقدم في استراتيجيات العلاج الشخصية.

الطرق: استعرضت الدراسة التجارب السريرية والتحليلات التلوية ودراسات الحالة الواقعية التي تفحص التدخلات مثل الميتفورمين، والأدوية المحاكية لمستقبلات GLP-1، وأدوية خافضة للغلوكوز أخرى. كما حللت استراتيجيات الوقاية، بما في ذلك تعديلات نمط الحياة وآثارها طويلة الأمد.

النتائج: أدت تعديلات نمط الحياة إلى تقليل الإصابة بمرض السكري من النوع 2 بنسبة 58%، بينما قللت الميتفورمين الإصابة بنسبة 31%. أظهرت العلاجات الناشئة مثل السيماغلوتيد والتيرزيباتيد تحسينات كبيرة في التحكم في نسبة السكر في الدم وعكس مرحلة ما قبل السكري. وكشف دمج سجلات المرضى عن تحسين تخصيص العلاج والتدخلات في الوقت المناسب. كما حافظ الالتزام طويل الأمد بالعلاج الدوائي على الحد من تقدم مرض السكري من النوع 2 وتقليل المخاطر.

الخاتمة: يعزز دمج سجلات الصيدلة والسجلات الطبية إدارة الأمراض المزمنة من خلال تحسين الرعاية الوقائية، والمراقبة، والتدخلات الشخصية. وتؤكد النتائج على أهمية الأنظمة الصحية المتكاملة وأهمية البحث المستمر للتصدي لزيادة وباء السكري من النوع 2.

الكلمات المفتاحية: مرض السكري من النوع 2، إدارة الأمراض المزمنة، سجلات الصيدلة، دمج السجلات الطبية، التدخلات الخاصة بنمط الحياة، الأدوية خافضة للغلوكوز، العلاج الشخصي.